Cognition Therapeutics, Inc. Common Stock (CGTX) Stock Price
CGTXStock
$1.03−64.96%52W
Market Cap$97.95M
P/E—
PEG Ratio—
Div yield—
Beta1.84
CGTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.48%
Price vs S&P 500 (4W)3.55%
VGM Score27.42
CGTX Earnings Surprise History
Q2 25-0.11est. -0.10
Q3 25-0.06est. -0.09
Q4 25-0.02est. -0.08
Q1 26-0.05est. -0.07
Q2 26-0.04est. -0.06
CGTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.11
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CGTXCognition Therapeutics, Inc. Common Stock | — | — | D | $1.03 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age-related degenerative diseases of the central nervous system and retina. Its lead candidate, CT1812, is an oral antagonist designed to cross the blood-brain barrier and selectively bind to the S2R complex. The company is advancing this approach through clinical development.